Rigel Pharmaceuticals (RIGL) Tax Provisions (2021 - 2026)
Rigel Pharmaceuticals' quarterly Tax Provisions came in at $3.0 million in Q1 2026, up 4520.0% year-on-year from $65000.0 in Q1 2025, and up 101.22% quarter-over-quarter from -$245.4 million in Q4 2025.
Rigel Pharmaceuticals has reported Tax Provisions for 4 years, with the latest figure at $3.0 million in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions rose 4520.0% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at -$242.3 million (down 25708.77% YoY), and the FY2025 full-year result was -$245.2 million, down 27931.67% from the prior year.
- Tax Provisions for Q1 2026 stood at $3.0 million, up from -$245.4 million in the prior quarter.
- The five-year high for Tax Provisions was $3.0 million in Q1 2026, with the low at -$245.4 million in Q4 2025.
- Average Tax Provisions over 3 years is -$40.2 million, with a median of $217000.0 recorded in 2025.
- Year-over-year, Tax Provisions slumped 27949.15% in 2025 and soared 4520.0% in 2026.
- Tracing RIGL's Tax Provisions over 3 years: stood at $881000.0 in 2024, then tumbled by 27949.15% to -$245.4 million in 2025, then jumped by 101.22% to $3.0 million in 2026.
- The last three Tax Provisions figures came in at $3.0 million (Q1 2026), -$245.4 million (Q4 2025), and -$280000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | -245.35 Mn |
| Sep 30, 2025 | -280,000.00 |
| Jun 30, 2025 | 369,000.00 |
| Mar 31, 2025 | 65,000.00 |
| Dec 31, 2024 | 881,000.00 |
| Dec 31, 2021 | -100,000.00 |
| Sep 30, 2021 | -136,000.00 |
| Jun 30, 2021 | -1.00 Mn |
| Mar 31, 2021 | 1.77 Mn |